ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Hanyang, Seoul

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Cancer
Small Cell Lung Carcinoma
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Neoplasm Metastasis

Lung Cancer trials near Hanyang, Seoul, KOR:

Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer (ARC-10)

to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung...

Active, not recruiting
Squamous Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Pemetrexed

Phase 2

Arcus Biosciences
Arcus Biosciences

Seoul, Korea, Republic of and 95 other locations

This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: DS-1062a

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seoul, Korea, Republic of and 83 other locations

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Seoul, Gangnam-gu, Korea, Republic of and 63 other locations

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer....

Enrolling
Non-small Cell Lung Cancer
Drug: MGY825

Phase 1

Novartis
Novartis

Seoul, Korea, Republic of and 15 other locations

to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: JDQ443
Drug: docetaxel

Phase 3

Novartis
Novartis

Seongnam-si, Gyeonggi-do, South Korea and 52 other locations

The purpose of this study is to assess the objective response rate (ORR) of immunotherapy-based combination therapy and to assess the safety and tole...

Enrolling
Advanced Non-Small Cell Lung Cancer
Drug: Docetaxel
Drug: Zimberelimab

Phase 2

Gilead Sciences
Gilead Sciences

Seoul, Korea, Republic of and 57 other locations

Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung...

Enrolling
Lung Cancer
EGFR Mutation-Related Tumors
Drug: BG-60366

Phase 1

BeiGene
BeiGene

Seoul, Seoul Teugbyeolsi, South Korea and 42 other locations

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-sma ...

Active, not recruiting
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Seoul, Korea, Republic of and 38 other locations

the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung...

Active, not recruiting
Lung Cancer
Drug: Itacitinib
Drug: Osimertinib

Phase 1, Phase 2

Incyte
Incyte

Seoul, Songpa-gu, Korea, Republic of and 30 other locations

with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Docetaxel
Drug: DS-1062a

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Seoul, South Korea and 210 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems